How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
HIV Market
- By Product Type: Antiretroviral Drugs (ARVs), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Diagnostic Tests, HIV Vaccines (under development)
- By Therapy Class: Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Strand Transfer Inhibitors (INSTIs), Entry Inhibitors
- By End User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutes
- By Patient Population: Treatment-Naive Patients, Treatment-Experienced Patients, Pregnant Women with HIV, Pediatric HIV Patients, Patients with HIV/TB Co-infection
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antiretroviral Drugs (ARVs) leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the HIV Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Therapy Class 5
End User 5
Patient Population 5
Companies profiled
Gilead Sciences
ViiV Healthcare
Johnson & Johnson
Merck & Co.
GlaxoSmithKline
AbbVie
Bristol-Myers Squibb
Pfizer
Roche
Mylan (now part of Viatris)
Cipla
Mitsubishi Tanabe Pharma
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →ViiV Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GlaxoSmithKline
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AbbVie
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bristol-Myers Squibb
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Pfizer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Roche
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Mylan (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cipla
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Mitsubishi Tanabe Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Viiv Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shionogi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Aurobindo Pharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,670M by 2033 · 8.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antiretroviral Drugs (ARVs)35.2
- Pre-Exposure Prophylaxis (PrEP)16.5
- Post-Exposure Prophylaxis (PEP)19.1
- Diagnostic Tests13.9
- HIV Vaccines (under development)15.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$988.6M → $1,688M · 6.9%
Europe$689.0M → $1,441M · 9.7%
Asia Pacific$629.1M → $1,253M · 9.0%
Latin America$389.5M → $745.6M · 8.5%
Middle East and Africa$299.6M → $597.5M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.252026
8.272027
8.282028
8.292029
8.292030
8.322031
8.342032
8.342033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Gilead Sciences16.8
- ViiV Healthcare17.2
- Johnson & Johnson11.1
- Merck & Co.12.0
- GlaxoSmithKline7.7
- AbbVie7.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type27.1%
Therapy Class20.4%
End User18.5%
Patient Population34.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.5
- Europe25.2
- Asia Pacific21.9
- Latin America13.0
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Gilead Sciences | 77 | 83 | 89 | 83 | 74 | 77 | 81 |
| ViiV Healthcare | 81 | 88 | 87 | 74 | 86 | 83 | 83 |
| Johnson & Johnson | 83 | 75 | 79 | 66 | 73 | 73 | 75 |
| Merck & Co. | 81 | 78 | 60 | 72 | 75 | 67 | 72 |
| GlaxoSmithKline | 73 | 68 | 56 | 70 | 55 | 71 | 66 |
| AbbVie | 61 | 64 | 67 | 53 | 51 | 54 | 58 |
| Bristol-Myers Squibb | 42 | 55 | 58 | 43 | 51 | 49 | 50 |
| Pfizer | 54 | 52 | 54 | 56 | 48 | 46 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Gilead Sciences
- ViiV Healthcare
- Johnson & Johnson
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Gilead Sciences | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| ViiV Healthcare | ◐ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Johnson & Johnson | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Merck & Co. | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| GlaxoSmithKline | ✓ | ◐ | − | ◐ | − | ◐ |
| AbbVie | ◐ | ◐ | ✓ | − | ◐ | − |
| Bristol-Myers Squibb | − | ◐ | ◐ | ◐ | − | ◐ |
| Pfizer | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1ViiV Healthcare83
2Gilead Sciences81
3Johnson & Johnson75
4Merck & Co.72
5GlaxoSmithKline66
6AbbVie58
7Pfizer52
8Bristol-Myers Squibb50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Gilead SciencesViiV Healthcare
Challenger2
Strong scale, closing on the leaders.
Johnson & JohnsonMerck & Co.
Contender2
Focused players with pockets of strength.
GlaxoSmithKlineAbbVie
Niche2
Specialists in a single segment or region.
Bristol-Myers SquibbPfizer
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across HIV Market — a $294M beachhead inside a $4.88B market.
Beachhead (SOM)$294Mobtainable near-term
Serviceable (SAM)$1.92Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Antiretroviral Drugs (ARVs)
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Pre-Exposure Prophylaxis (PrEP)
Strong fit — clear ROI and a fast path to value.
End user64 fit
Post-Exposure Prophylaxis (PEP)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapy Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel26%
Digital / self-serve24%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win HIV Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified23%
Evaluation14%
Closed-won8%
$13.7KCAC
$72KLTV
5.3:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
HIV Market is a durable-growth opportunity — $9.15B by 2033, compounding at 6.8%.
TAM · 2025$5.40Btoday
TAM · 2033$9.15Bforecast
CAGR6.8%2027–2033
Cumulative$64.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.15BTotal addressable market
SAM$3.56BServiceable available market
SOM$728MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.8% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.15BLarge & growingTAM by 2033 at 6.8% CAGR
$3.56BServiceable nowreachable with today’s model
$728MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.14BBear4.4% CAGR
$9.15BBase6.8% CAGR
$11.7BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapy Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
HIV Market — a $6.33B market by 2033. Plan: grow share from 7.3% to 12.0%.
Market size · 2033$6.33Btotal addressable
Market CAGR11.3%2027–2033
Target share12.0%from 7.3% today
Revenue ambition$760Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 12.0% | On track |
| Revenue | $471M | $760M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.7% | 45.2% | At risk |
| Customer retention | 89.3% | 92.1% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapy Class capability
A defensible second engine — invest in Therapy Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapy Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $84M capacity & capability investment
- Greenlight bolt-on M&A in Therapy Class
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the HIV Market conversation — a $5.55B market you can size, segment and defend in minutes.
Market size · 2033$5.55Btotal opportunity
Growth5.0%CAGR to 2033
Addressable buyers1,571+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 3 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Gilead SciencesViiV HealthcareJohnson & JohnsonMerck & Co.GlaxoSmithKlineAbbVieBristol-Myers SquibbPfizer+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your HIV Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
HIV Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Hiv Rapid Test Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportHiv Treatment Drug Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportHiv Vaccine Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportHiv-Aids Testing Instruments Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHIV-associated Nephropathy Treatment Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportHJT Cell Market
Market size, share, segmentation and regional forecast.
$552M market · 2025 base year
View reportHMC and HBM Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportHMDS (CAS No. 999-97-3) Market
Market size, share, segmentation and regional forecast.
$794M market · 2025 base year
View reportH-MET-OIPR HCL CAS 85391-05-5 Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportHMGB1 ELISA Kit Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportHmg-Coa Reductase Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportHMI Panel PC Market
HMI Panel PC Market is valued at USD 1.38 Billion in 2025 and is expected to reach USD 2.1 Bill…
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.